<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039114</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-102 (CITADEL-102)</org_study_id>
    <nct_id>NCT03039114</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)</brief_title>
  <official_title>An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined
      with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular
      lymphoma (FL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of INCB050465 in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs)</measure>
    <time_frame>Screening through 30-35 days after end of treatment, up to approximately 32 months per subject</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate based on Lugano classification criteria</measure>
    <time_frame>Protocol-defined timepoints throughout the treatment period, up to approximately 31 months per subject</time_frame>
    <description>Defined as percentage of subjects with a complete response (CR) and partial response (PR), as determined by investigator assessment of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate based on Lugano classification criteria</measure>
    <time_frame>Protocol-defined timepoints throughout the treatment period, up to approximately 31 months per subject</time_frame>
    <description>Defined as percentage of subjects who achieve a best overall response of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Protocol-defined timepoints throughout the treatment period, up to approximately 31 months per subject</time_frame>
    <description>Defined as time from first documented evidence of CR or PR until earliest date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Protocol-defined timepoints throughout the treatment period, up to approximately 31 months per subject</time_frame>
    <description>Defined as time from the date of the first dose of study drug until the earliest date of disease progression (determined by radiographic disease assessment/Lugano classification criteria) or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of the first dose of study drug until death due to any cause, assessed up to approximately 44 months per subject</time_frame>
    <description>Defined as the time from the date of the first dose of study drug until death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>INCB050465 + Hexal and Gazyvaro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.</description>
    <arm_group_label>INCB050465 + Hexal and Gazyvaro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hexal</intervention_name>
    <description>Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.</description>
    <arm_group_label>INCB050465 + Hexal and Gazyvaro</arm_group_label>
    <other_name>Bendamustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gazyvaro</intervention_name>
    <description>Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.</description>
    <arm_group_label>INCB050465 + Hexal and Gazyvaro</arm_group_label>
    <other_name>Gazyva®</other_name>
    <other_name>Obinutuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed FL.

          -  Documented CD20+ FL.

          -  Relapsed or refractory to any prior rituximab-containing regimen.

          -  Previously treated with a maximum of 4 cancer-directed treatment regimens.

          -  At least 1 measurable lesion &gt; 1.5 cm in at least 1 dimension by computed tomography
             or magnetic resonance imaging.

          -  Must be willing to undergo an incisional or excisional lymph node biopsy of accessible
             adenopathy or provide the most recent, available archived tumor biopsy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

        Exclusion Criteria:

          -  Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade
             3B FL.

          -  History of central nervous system lymphoma (either primary or metastatic).

          -  Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host
             disease following allogeneic transplant or autologous stem cell transplant within the
             last 3 months before the date of the first dose of study drug administration.

          -  Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
             half-lives (whichever is longer) before the first dose of study drug.

          -  Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.

          -  Prior treatment with bendamustine (within 12 months of the start of study treatment).
             Subjects with prior bendamustine treatment (&gt; 12 months before the start of study
             treatment) are eligible if they meet the following criteria:

               -  Did not discontinue because of tolerability concerns.

               -  Achieved either partial or CR to the bendamustine regimen of at least 12 months
                  in duration before relapse/progression.

               -  Experienced progression following a regimen containing an alkylating agent.

          -  Received prior obinutuzumab.

          -  Received rituximab within 4 weeks of study start.

          -  Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date
             of study drug administration except for stable chronic toxicities (≤ Grade 2) not
             expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).

          -  Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days
             before the date of study start.

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
             (eg, subjects in whom re-administration with rituximab would be contraindicated for
             safety reasons).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fitzroy Dawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Health</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scripps Clinical Research Services</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-652-5538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders (CCBD) - Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>240-482-0526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-436-1752</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-488-2918</phone>
      <phone_ext>121</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenvile Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>864-455-3735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FN Ostrava / Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420 59 737 2088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 78 66 71 08</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 35 45 83 39</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36 20943 6465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Ematologia LA Seragnoli</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39 051 214 3227</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39 030 399 6269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Mater Domini</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39 030 399 6269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>A Coruna</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 98 195 0172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parc de Salut MAR - Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 93 248 3343</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 93 497 8574</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 91 586 8394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 91 550 4800</phone>
      <phone_ext>2548</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 91 207 1247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 94 825 5400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 95 501 3273</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular lymphoma</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>phosphatidylinositol 3-kinase (PI3K)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

